Can't disagree with the timeline you post Steady_T - assuming it takes until 2015 to get started, an endpoint with the FDA (barring some sort of emergency use allowance - given that is unlikely) in 2016 for approval is a probability.
The only caveat to what you post that I might contradict is this.
IF (and yes - it is another if) the trials look really promising post Phase I and Phase II, then interest in NNVC stock will also tend to spike prior to drug testing completion in Phase III, and at least prior to final FDA approval.
Speculation alone could easily drive prices upwards prior to there being actual revenue - or somebody in big Pharma could attempt a liscence or partnership could materialize.
But - until TOX is completed, and until the needed stocks of Flucide are in hand to do the trials - this company's stock is subject to rumor, gossip and innuendo to drive market perception of it's actual value.
News 
Market Data 
Discover 
